<DOC>
	<DOCNO>NCT00995787</DOCNO>
	<brief_summary>The primary aim study evaluate safety tolerability AZD1656 T2DM patient treat metformin sulfonylurea .</brief_summary>
	<brief_title>Safety Tolerability AZD1656 Type 2 Diabetes Mellitus ( T2DM ) Patients Treated With Metformin Sulfonylurea</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male female nonchildbearing potential Patients treat combination Metformin SU ( glyburide , glimepiride , glibenclamide , glipizide gliclazide ) stable dos least 2 month prior enrolment visit Patients FPG range 6,0 14 mmol/L ( 108 250 mg/dL ) enrolment morning randomisation History ischemic heart disease , symptomatic heart failure , stroke , transitory ischemic attack symptomatic peripheral vascular disease Impaired renal function term GFR &lt; 60 ml/min Use insulin , glitazones , gemfibrozil , warfarin , amiodarone within 3 month prior enrolment ( screen ) use potent CYP450 inhibitor , e.g. , ketoconazole within 14 day randomisation</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Type II diabetes mellitus</keyword>
	<keyword>metformin</keyword>
	<keyword>sulfonylurea</keyword>
</DOC>